Astellas decides not to pursue CV Therapeutics
This article was originally published in Scrip
Astellas has decided not to raise its $16 per share bid for CV Therapeutics following Gilead Sciences agreed $20 per share offer. It will now withdraw its planned acquisition and the legal action related to it.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.